Showing results (41-50 of 161) with videos related to

Sort By:
Pageof 17
BMJ Oncology|April 25, 2025
Correction: Association between rheumatoid arthritis and risk of radiotherapy toxicity: a systematic review
BMJ Oncology|January 31, 2025
Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncologyMedhavi Gupta, Othman Salim Akhtar, Bhavyaa Bahl, et al.
BMJ Oncology|January 31, 2025
Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort studyMelissa Ruth Gannon, David Dodwell, Katie Miller, et al.
BMJ Oncology|January 31, 2025
Circulating tumour cell clusters: isolation, biological significance and therapeutic implicationsYufan Yang, Guanyin Huang, Jingru Lian, et al.
BMJ Oncology|March 6, 2025
Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastasesDebora M Meijer, Siddh van Oost, Jessica P Roelands, et al.
BMJ Oncology|March 6, 2025
Whole-body integral dose and post-radiotherapy lymphocytopaenia in solid tumoursNuradh Joseph, Lanka Alagiyawanna, Thilina Ruwanpura, et al.
BMJ Oncology|March 18, 2025
TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaKaifeng Jin, Jingtong Xu, Lingkai Zhang, et al.
BMJ Oncology|August 1, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysisElias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq, et al.
BMJ Oncology|January 31, 2025
Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old menEmil Järbur, Erik Holmberg, Thomas Björk-Eriksson, et al.
BMJ Oncology|January 31, 2025
Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapyRebecca C Obeng, Tahseen H Nasti, Kylee Martens, et al.
Pageof 17